IL-27 in combination with anti-PD-1 can be anti-cancer or pro-cancer.
J Theor Biol
; 579: 111704, 2024 02 21.
Article
en En
| MEDLINE
| ID: mdl-38104658
ABSTRACT
Interleukin-27 (IL-27) is known to play opposing roles in immunology. The present paper considers, specifically, the role IL-27 plays in cancer immunotherapy when combined with immune checkpoint inhibitor anti-PD-1. We first develop a mathematical model for this combination therapy, by a system of Partial Differential Equations, and show agreement with experimental results in mice injected with melanoma cells. We then proceed to simulate tumor volume with IL-27 injection at a variable dose F and anti-PD-1 at a variable dose g. We show that in some range of "small" values of g, as f increases tumor volume decreases as long as fPalabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Interleucina-27
/
Melanoma
Límite:
Animals
Idioma:
En
Revista:
J Theor Biol
Año:
2024
Tipo del documento:
Article